Justin Renz

Justin has served as the Chief Financial & Operations Officer since 2023. Before that, Justin had served as our Chief Financial Officer since June 2020. Justin brings over 20 years of experience in the biopharmaceutical industry, with an extensive array of financial and operational experience.

Prior to Ardelyx, Justin served as the president and chief financial officer of Correvio Pharma, a global specialty pharmaceutical company dedicated to the commercialization of cardiovascular and infectious disease products, where he led the sale of the company to ADVANZ PHARMA in May 2020. Prior to Correvio, Justin was executive vice president, chief financial officer and treasurer of Karyopharm Pharmaceuticals, where he led core business and finance functions and multiple financings. Before Karyopharm, Justin was executive vice president and chief financial officer at Zalicus Inc. (formerly CombinatoRx, Inc.), which he joined in 2006. At Zalicus, Justin oversaw multiple rounds of equity and debt financings, led the company’s asset monetization strategy and was instrumental in the reverse merger and sale of Zalicus to EPIRUS Biopharmaceuticals Inc. in July 2014. Earlier in his career, Justin held numerous positions of increasing responsibility at EMD Serono Inc., ArQule, Inc., Coley Pharmaceutical Group and Millipore Corporation.